Results 11 to 20 of about 145,099 (296)

Novel Method for High-Throughput Full-Length IGHV-D-J Sequencing of the Immune Repertoire from Bulk B-Cells with Single-Cell Resolution

open access: yesFrontiers in Immunology, 2017
Efficient and accurate high-throughput DNA sequencing of the adaptive immune receptor repertoire (AIRR) is necessary to study immune diversity in healthy subjects and disease-related conditions.
Stefano Vergani   +7 more
doaj   +1 more source

Determinants of Time-to-Death of Chronic Lymphocytic Leukemia Patients at Felege Hiwot Referral Hospital, Bahir Dar, Ethiopia

open access: yesCancer Informatics, 2023
Background: Leukemia is a group of cancers that usually begin in the bone marrow and results in a large number of abnormal white blood cells. Chronic Lymphocytic Leukemia is the most prevalent leukemia in Western countries, with an estimated incidence ...
Gedam Derbew Addisia   +9 more
doaj   +1 more source

The protective role of the microenvironment in hairy cell leukemia treatment: Facts and perspectives

open access: yesFrontiers in Oncology, 2023
Hairy cell leukemia (HCL) is an incurable, rare lymphoproliferative hematological malignancy of mature B cAlthough first line therapy with purine analogues leads to positive results, almost half of HCL patients relapse after 5-10 years, and standard ...
Ernesto Gargiulo   +9 more
doaj   +1 more source

Chronic lymphocytic leukemia and the central nervous system: a clinical and pathological study. [PDF]

open access: yes, 1996
Chronic lymphocytic leukemia is the most common human leukemia but infrequently causes neurologic symptoms. We have reviewed all previously reported cases of chronic lymphocytic leukemia in the CNS along with three new cases; one patient was diagnosed ...
Cramer, SC   +3 more
core   +2 more sources

T LYMPHOCYTE SUBSETS STUDIED IN A PATIENT WITH TWO ASSOCIATED HEMATOLOGIC NEOPLASIAS – CHRONIC LYMPHOCYTIC LEUKEMIA B AND CHRONIC MYELOID LEUKEMIA [PDF]

open access: yesRomanian Journal of Medical Practice, 2019
Quantification of various cellular subpopulations facilitates the monitoring of hematological diseases, including chronic lymphocytic leukemia. Variations in the proportions of regulatory T cells in peripheral blood have been described in patients with
Georgiana Ene   +3 more
doaj   +1 more source

Case report: Identification of atypical mantle cell lymphoma with CCND3 rearrangement by next-generation sequencing

open access: yesFrontiers in Oncology, 2023
The t(11;14) (q13;q32) translocation resulting in overexpression of cyclin D1 is the major oncogenic mechanism in mantle cell lymphoma (MCL). Most MCLs can be diagnosed based on morphological features, cyclin D1 expression, and IGH/CCND1 rearrangement ...
Luomengjia Dai   +21 more
doaj   +1 more source

Targeting Brutons Tyrosine Kinase in Chronic Lymphocytic Leukemia at the Crossroad between Intrinsic and Extrinsic Pro-survival Signals [PDF]

open access: yes, 2016
Chemo immunotherapies for chronic lymphocytic leukemia (CLL) showed a positive impact on clinical outcome, but many patients relapsed or become refractory to the available treatments.
Facco, Monica   +7 more
core   +1 more source

Multi-Compartment and Multi-Host Vector Suite for Recombinant Protein Expression and Purification

open access: yesFrontiers in Microbiology, 2018
Recombinant protein expression has become an invaluable tool in basic and applied research. The accumulated knowledge in this field allowed the expression of thousands of protein targets in a soluble, pure, and homogeneous state, essential for ...
Claudia Ortega   +9 more
doaj   +1 more source

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. [PDF]

open access: yes, 2019
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or ...
Bairey, Osnat   +19 more
core   +3 more sources

Home - About - Disclaimer - Privacy